Amplifon stock extends year-to-date decline as GN Hearing deal shapes outlook
Published on 08/21/2026 at 19:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amplifon S.p.A. (ISIN IT0004056880) stock has been under pressure in August 2026, with the shares closing at EUR 11.85 on August 21, 2026, leaving them more than 10 percent below their level at the start of the year and reflecting investor unease around a sector shakeup and mixed signals from key partner GN Hearing.
The trading pattern over August 20-21, 2026 shows the stock reacting to fresh information on GN’s performance and its planned sale of the hearing business to Amplifon, even as Amplifon itself reports modest revenue growth and improved profitability for the second quarter of 2026.
For investors, the tension between short-term price weakness and a structurally significant acquisition now dominates the story around Amplifon stock.
Share price slips despite GN Hearing deal progress
Market data compiled from the FTSE MIB performance table for August 21, 2026 shows Amplifon closing that trading session at EUR 11.85, down 2.99 percent for the day and modestly higher than the prior-day close, underscoring that the rebound after a sharp drop has been limited.
A same-day sector commentary notes that Amplifon finished August 20, 2026 at EUR 11.68, which was 10.9 percent below its level at the beginning of 2026, and that the slight move to EUR 11.85 on August 21, 2026 still left the stock down 13.85 percent year-to-date, underperforming the broader Italian market.
The price context indicates that investors have been reluctant to chase Amplifon stock higher, even as one major corporate transaction promises to expand the group’s footprint in hearing care.
In a transaction announced in March 2026 and reiterated in coverage on August 21, 2026, GN agreed to sell its entire Hearing business to Amplifon for a total consideration of DKK 17.0 billion, equivalent to $2.66 billion on a cash- and debt-free basis, split between DKK 12.6 billion in cash and 56 million newly issued Amplifon shares.
Additional reporting on August 20, 2026 highlights that the deal is expected to close toward the end of 2026 and that the share component will be subject to a staggered lock-up period of 9 to 15 months after closing, a structure that could limit immediate selling pressure from GN but will leave a sizable external holder in Amplifon’s shareholder base.
This combination of cash and equity financing, plus the lock-up, means Amplifon is taking on both integration and capital-market execution risk, even as it secures a leading global hearing-aids business at a time when demographics support long-term demand growth.
Q2 2026 results show modest growth but stronger margins
To judge whether the GN Hearing acquisition comes on top of a solid base, investors have turned to Amplifon’s latest published results, which include a Q2 2026 revenue figure of EUR 606 million, as highlighted in a half-year 2026 summary.
This Q2 2026 revenue represents a 2.2 percent increase compared with the same quarter of 2025, showing that the company is still growing but at a more measured pace than in earlier years and slightly below many high-growth healthcare peers.
More important for the equity story, Amplifon identifies an organic revenue increase of 4.7 percent in Q2 2026, described as its strongest organic growth rate in two years, suggesting that underlying demand for hearing-care services and devices is improving even as reported growth is dampened by currency and consolidation effects.
Profitability also moved in the right direction in Q2 2026: the company reports an adjusted EBITDA margin of 25.8 percent for the quarter, which is 0.9 percentage points higher than in Q2 2025 and indicates a gradual but tangible improvement in operating efficiency and mix.
On the cash side, Amplifon’s half-year 2026 overview shows that adjusted free cash flow rose to EUR 68 million in the first six months of 2026, up from EUR 40 million in the first half of 2025, a gain of EUR 28 million and an increase of 70 percent that gives the company more flexibility to fund acquisitions and organic expansion.
The combination of modest revenue growth, stronger organic trends, better margins, and significantly higher free cash flow positions Amplifon as a company that is tightening its operations just as it prepares to absorb a large new business from GN Hearing.
GN’s weaker Q2 raises questions for the sector
The timing of the stock’s recent slide coincides with GN’s own Q2 2026 report, which shows GN Hearing revenue for the quarter declining to EUR 273 million and its adjusted EBITDA margin slipping to 18.1 percent, indicating pressure on both top line and profitability in the hearing division that Amplifon is set to acquire.
In commentary on August 21, 2026, the decline in GN Hearing’s performance is cited as one reason for investors’ cautious stance on Amplifon, given that the Italian group will be taking over a business that is currently underperforming versus prior periods and may require operational turnaround efforts.
The margin comparison is stark: Amplifon’s adjusted EBITDA margin of 25.8 percent in Q2 2026 stands 7.7 percentage points above GN Hearing’s 18.1 percent margin, reinforcing the view that Amplifon runs a more profitable model today but may need to lift the acquired business toward its own standards.
Management at GN has defended the sale and its valuation, and a report on August 21, 2026 notes that the CEO rejected criticism describing the deal terms as scandalous, arguing that the divestment and the mix of cash and shares serve GN’s strategic priorities even if some investors are dissatisfied with short-term pricing.
For Amplifon shareholders, the key question is not the fairness of GN’s sale price but whether Amplifon can replicate its own margin profile in the acquired business and sustain organic growth once the integration and cost synergies are executed.
Analyst view and market expectations
Analyst sentiment has started to reflect this balance of opportunity and execution risk: a broker research update on August 21, 2026 reports that the average target price for Amplifon stands at EUR 13.44, compared with a last close of EUR 11.85, implying potential upside of 13.45 percent if the company hits its earnings and integration goals.
Within that same overview, the year-to-date performance for Amplifon is shown as a decline of 13.85 percent, which means the stock has lagged many domestic peers and suggests that expectations for integration risk and sector uncertainty are already embedded in the valuation.
The consensus data also point to the next scheduled catalyst: the agenda section lists a Q3 2026 results publication date of October 29, 2026, when Amplifon is expected to give investors an update on both its underlying business and the progress of the GN Hearing transaction.
In the meantime, management has reaffirmed its guidance for fiscal 2026, calling for organic revenue growth of more than 3 percent and an improvement of the EBITDA margin by 1 percentage point versus the prior year, targets that will require continued operational discipline but appear aligned with the recent Q2 patterns.
If the company can deliver organic growth of at least 3 percent for 2026 and lift the margin by the guided 1 percentage point while integrating GN Hearing’s assets, the gap between the current share price and the average target price could narrow, although execution missteps would likely be punished quickly given the stock’s recent volatility.
Amplifon’s core hearing-care offering
Beyond the numbers, Amplifon’s business revolves around providing hearing solutions through a global network of specialized clinics, offering hearing tests, personalized fitting of hearing aids, and ongoing aftercare.
At the product level, the company focuses on modern digital hearing aids and hearing-care services tailored to individual needs, combining devices from leading manufacturers with its own fitting protocols and customer support to improve patients’ quality of life.
This emphasis on service-led hearing care means that the GN Hearing acquisition, which brings in a major supplier of hearing-aid technology, could deepen Amplifon’s access to advanced devices while expanding its ability to offer integrated solutions across hardware and service.
Stock level and investor takeaway
As of the close on August 21, 2026, Amplifon stock trades on Borsa Italiana at EUR 11.85, a level that leaves the shares below their average analyst target and more than 10 percent under their price at the start of 2026, reflecting both sector headwinds and the market’s cautious assessment of the upcoming GN Hearing integration.
For retail investors, the current price and the quantified gap to consensus highlight how much weight the market is placing on execution in the GN transaction and on Amplifon’s ability to sustain organic growth and margin expansion through 2026.
Fact box
Company: Amplifon S.p.A.
ISIN: IT0004056880
Ticker: AMP
Exchange: Borsa Italiana
Price (as of August 21, 2026): EUR 11.85
Sector / Industry: Health care - hearing care services and devices
Index membership: FTSE MIB
More on Amplifon stock
Amplifon’s recent combination of modest top-line growth, improving margins, and a transformative acquisition has created a complex picture for Amplifon stock, with the next major update expected when the company reports Q3 2026 results.
